Each 100 mg of Qivigy (immune globulin) administered by subcutaneous injection for immunodeficiency treatment

Qivigy (immune globulin subcutaneous [human], 20% solution) is a subcutaneous immunoglobulin (SCIG) replacement therapy used to provide passive immunity in patients with primary and secondary immunodeficiencies. This code represents a per-100 mg billing unit for the subcutaneous administration of this specific IgG formulation. Units billed must reflect the actual dosage administered, rounded to the nearest 100 mg.

This code applies when Qivigy is administered to patients with documented primary immunodeficiency (PID) disorders such as common variable immunodeficiency (CVID), X-linked agammaglobulinemia, or other conditions resulting in inadequate antibody production. It is also appropriate for secondary immunodeficiency states where IgG replacement is medically necessary. Supporting documentation should include the diagnosis, documented IgG trough levels, dosage ordered, and route of administration confirming subcutaneous delivery.

• Do not confuse with IVIG codes (e.g., J1566, J1568, J1569): Qivigy is strictly a subcutaneous formulation; using an intravenous IgG code for this product—or vice versa—constitutes a coding error and may trigger payer audits.
• Unit calculation is critical: Bill one unit per 100 mg administered; if the patient receives 8,000 mg, bill 80 units. Undercoding or overcoding due to incorrect unit conversion is a frequent error.
• Payer prior authorization requirements: Most payers, including Medicare, require prior authorization and documented failure or intolerance of alternative IgG therapies; ensure the medical record reflects this before claim submission.